Emergent BioSolutions
Emergent BioSolutions Inc., a leading biopharmaceutical company headquartered in the United States, specialises in developing and manufacturing vaccines and therapeutics for public health threats. Founded in 1998, the company has achieved significant milestones, including the acquisition of key assets that bolster its position in the biodefence and infectious disease sectors. With a strong operational presence across North America and Europe, Emergent BioSolutions focuses on core products such as vaccines for anthrax and smallpox, as well as treatments for opioid overdose. What sets the company apart is its commitment to addressing urgent health needs through innovative solutions and strategic partnerships. Recognised for its expertise in biodefence, Emergent BioSolutions continues to play a pivotal role in enhancing global health security.
DitchCarbon Score
How does Emergent BioSolutions's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Emergent BioSolutions's score of 33 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Emergent BioSolutions's reported carbon emissions
In 2023, Emergent BioSolutions reported total carbon emissions of approximately 35,292,000 kg CO2e, comprising 16,856,000 kg CO2e from Scope 1 emissions and 18,436,000 kg CO2e from Scope 2 emissions. The previous year, 2022, saw total emissions of about 40,434,000 kg CO2e, with Scope 1 emissions at 19,334,000 kg CO2e and Scope 2 emissions at 21,099,000 kg CO2e. This indicates a reduction of approximately 5,142,000 kg CO2e in total emissions from 2022 to 2023. Emergent BioSolutions has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets through initiatives such as the Science Based Targets initiative (SBTi). The company has not reported any formal climate pledges or reduction initiatives. The emissions intensity per full-time equivalent employee (FTE) was reported at about 13,900 kg CO2e in 2023, slightly higher than the 13,600 kg CO2e reported in 2022. This data reflects the company's ongoing commitment to monitoring and reporting its carbon footprint, although further commitments or targets for emissions reduction have not been established. All emissions data is sourced directly from Emergent BioSolutions Inc. and is not cascaded from any parent or related organization.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 19,334,000 | 00,000,000 |
| Scope 2 | 21,099,000 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Emergent BioSolutions is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
